$2995 | Single User
$4495 | Multi User
$8995 | Site License
$14995 | Global License

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2017 [Report Updated: 01-09-2017]

Published by Current Partnering: 01 Sep 2017 | 117449 | In Stock

Introduction

The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies.


This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report covers details of co-promotion and co-marketing agreements from 2010 to 2017.


For pharmaceutical and biotechnology professionals, the report supplies a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of all co-promotion and co-marketing deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.


Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


The initial chapters of this report provide an orientation of co-promotion and co-marketing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of each type of deal.


Chapters 3 and 4 provide an overview of the structure of co-promotion and co-marketing deals, respectively. Each chapter includes numerous case studies to enable understanding of both pure co-promotion/marketing deals and multicomponent deals where co-promotion/marketing forms a part.


Chapter 5 provides a review of the leading co-promotion and co-marketing deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.


Chapter 6 provides a review of the top 50 most active biopharma companies in co-promotion and co-marketing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.


Chapter 7 provides a comprehensive and detailed review of co-promotion and co-marketing deals signed and announced since 2010 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.


The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.


The report also includes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing deal making since 2010.


In addition, a comprehensive appendix is provided organized by co-promotion and co-marketing company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In conclusion, this report provides everything a prospective dealmaker needs to know about co-promotion and co-marketing partnering in the research, development and commercialization of technologies and products.


Key benefits


Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides the reader with the following key benefits:


In-depth understanding of co-promotion and co-marketing deal trends since 2010

Analysis of the structure of co-promotion and co-marketing agreements with numerous real life case studies

Comprehensive access to over 700 actual co-promotion and co-marketing deals entered into by the world’s biopharma companies

Insight into the terms included in a co-promotion and co-marketing agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report is intended to provide the reader with an in-depth understanding of the co-promotion and co-marketing trends and structure of deals entered into by leading biopharma companies worldwide.


Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 includes:


Trends in co-promotion and co-marketing dealmaking in the biopharma industry since 2010

Analysis of co-promotion and co-marketing deal structure

Case studies of real-life co-promotion and co-marketing deals

Access to over 700 co-promotion and co-marketing deal records

Detailed access to actual co-promotion contract documents

The leading co-promotion and co-marketing deals by value since 2010

Most active co-promotion and co-marketing dealmakers since 2010

The leading co-promotion and co-marketing partnering resources


In Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017, the available contracts are listed by:


Company A-Z

Headline value

Stage of development at signing

Therapeutic area

Technology area


Each deal title links via Weblink to an online version of deal record as found in the Current Agreements deals and alliances database, providing easy access to each deal record on demand.


The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive access to records for over 700 co-promotion and co-marketing deals. Analyzing actual contract agreements allows assessment of the following:


What are the precise co-promotion and co-marketing rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Table of Contents
for Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2017 [Report Updated: 01-09-2017]

  • Executive Summary

    Chapter 1 – Introduction

    Chapter 2 – Trends in co-promotion and co-marketing dealmaking

    2.1. Introduction

    2.2. Difference between co-promotion and co-marketing deals

    2.3. Trends in co-promotion deals since 2010

    2.3.1. Co-promotion and co-marketing dealmaking by year, 2010 to 2017

    2.3.2. Co-promotion and co-marketing dealmaking by phase of development, 2010 to 2017

    2.3.3. Co-promotion and co-marketing dealmaking by industry sector, 2010 to 2017

    2.3.4. Co-promotion and co-marketing dealmaking by therapy area, 2010 to 2017

    2.3.5. Co-promotion and co-marketing dealmaking by technology type, 2010 to 2017

    2.3.6. Co-promotion and co-marketing dealmaking by most active company, 2010 to 2017

    2.4. When co-marketing can be useful

    2.5. When co-marketing is the only option

    2.6. Pure deals and multi-component deals

    2.6.1. Attributes of pure co-promotion deals

    2.6.2. Attributes of co-promotion in multi-component deals

    2.7. Reasons for including co-promotion options in a deal

    2.8. Uptake of co-promotion rights

    2.9. Co-promotion rights as bargaining chips

    2.10. Aligning partners to make the co-promote work

    2.11. The future of co-promotion as part of multicomponent deals

    Chapter 3 – Overview of co-promotion deal structure

    3.1. Introduction

    3.2. Pure versus multi-component co-promotion deals

    3.3. Pure co-promotion agreement structure

    3.3.1. Example co-promotion agreements

    3.3.1.a. Case study 1: Allergan – MAP Pharmaceuticals

    3.3.1.b. Case study 2: Genzyme – Veracyte

    3.4. Co-promotion rights as part of a wider alliance agreement

    3.4.1. Example co-promotion option clauses

    3.4.1.a. Case study 3: Takeda Pharmaceutical– Orexigen Therapeutics

    3.4.1.b. Case study 4: Celgene – Acceleron Pharma

    3.4.2. Example co-promotion right clauses

    3.4.2.a. Case study 5: Takeda – Orexigen

    3.4.2.b. Case study 6: Abbvie – Receptos

    3.5. Embedded co-promotion rights enabling third party engagement

    3.5.1. Example co-promotion clauses enabling third party engagement

    3.5.1.a. Case study 7: Astellas – Ambit Biosciences

    Chapter 4 – Overview of co-marketing deal structure

    4.1. Introduction

    4.2. Co-marketing agreement structure

    4.2.1. Example co-marketing agreements

    4.2.1.a. Case study 8: AstraZeneca –Ironwood Pharmaceuticals

    4.3. Co-marketing rights as part of a wider alliance agreement

    4.3.1. Example co-marketing right clauses

    4.3.1.a. Case study 9: Lundbeck – Myriad Genetics

    Chapter 5 – Leading co-promotion and co-marketing deals

    5.1. Introduction

    5.2. Top co-promotion and co-marketing deals by value

    Chapter 6 – Top 50 most active co-promotion and co-marketing dealmakers

    6.1. Introduction

    6.2. Top 50 most active co-promotion and co-marketing dealmakers

    Chapter 7 – Co-promotion and co-marketing agreement contracts directory 2010- 2017

    7.1. Introduction

    7.2. Co-promotion and co-marketing deals with contracts 2010 to 2017

    Appendices

    Appendix 1 – Co-promotion and co-marketing deals by company A-Z

    Appendix 2 – Co-promotion and co-marketing deals by stage of development

    Appendix 3 – Co-promotion and co-marketing deals by deal type

    Appendix 4 – Co-promotion and co-marketing deals by therapy area

    Appendix 5 – Co-promotion and co-marketing deals by technology type

    Appendix 6 –Deal type definitions

    About Wildwood Ventures

    Current Partnering

    Current Agreements

    Recent report titles from Current Partnering

    TABLE OF FIGURES

    Figure 1: Definition of co-promotion and co-marketing

    Figure 2: Trends in co-promotion and co-marketing deal announcements, 2010 to 2017

    Figure 3: Co-promotion and co-marketing deals signed at each phase of development, 2010 to 2017

    Figure 4: Co-promotion and co-marketing deals by industry sector, 2010 to 2017

    Figure 5: Co-promotion and co-marketing deals by therapy area, 2010 to 2017

    Figure 6: Co-promotion and co-marketing deals by technology type, 2010 to 2017

    Figure 7: Top 50 most active co-promotion and co-marketing dealmakers, 2010 to 2017

    Figure 8: Situations where co-marketing can prove useful

    Figure 9: Key components of a pure co-promotion deal

    Figure 10: Key components of a multi-component co-promotion deal

    Figure 11: Example deals where co-promotion options have been actively exercised, since 2000

    Figure 12: Issues in implementing co-promotion agreements

    Figure 13: Co-promotion agreements – what should a contract include?

    Figure 14: Components of the co-promotion deal structure

    Figure 15: Components of the co-marketing deal structure

    Figure 16: Top co-promotion and co-marketing deals by value since 2010

    Figure 17: Most active co-promotion and co-marketing dealmakers 2010 to 2017

Additional Details

Publisher

Current Partnering

Publisher Information

Reference

117449 | CP2050

Number of Pages

481

Report Format

PDF

Current Partnering Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Which companies excel in diabetes drug marketing and why?
Scope With both the insulin and non-insulin segments of the diabetes market expected to become more ...
01 May 2015 by FirstWord Pharma USD $695 More Info
Physician Views: Do doctors share industry’s desire for the FDA to relax its policies on off-label promotion of drugs?
Scope Industry appears to be making a concerted push to pressure the FDA to relax what they believe ...
01 May 2015 by FirstWord Pharma USD $695 More Info
Physician Views – Which multiple sclerosis players do the best marketing job? – FirstWord polls neurologists in the US and 5EU
ScopeThe multiple sclerosis market has undergone notable change over the past 2 years, primarily due...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Innovations in Multichannel Marketing
IntroductionFirstWord goes beyond the multichannel marketing hype to explore what multichannel marke...
01 Aug 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Which diabetes company does the best marketing job? What is key for companies launching products?
ScopeThe importance of marketing is increasingly coming to the fore as diabetes-focused companies ba...
01 Aug 2013 by FirstWord Pharma USD $695 More Info
Effective sales and marketing strategies for drugs with companion diagnostics
IntroductionTo fully exploit the commercial advantages of companion diagnostics, Pharma companies ne...
01 May 2013 by FirstWord Pharma USD $695 More Info
Digital Doctors: Marketing to Online Networks (2nd Edition)
IntroductionPhysicians are digital As smartphones and tablets become ubiquitous among physicians, th...
01 Mar 2013 by FirstWord Pharma USD $695 More Info
Big Data in Pharma Marketing
IntroductionBig data - the huge volume of digital data generated worldwide - continues to grow expon...
01 Jan 2013 by FirstWord Pharma USD $695 More Info
Closing the Loop: delivering real-world commercial benefit from closed-loop marketing
IntroductionYour step-by-step guide to adapting to real time change.Over the past decade, closed loo...
01 Jan 2013 by FirstWord Pharma USD $695 More Info
Effective Sales and Marketing Strategies for Orphan Drugs
IntroductionThe real potential for orphan drug pharma marketingWith drug pipelines moving from essen...
01 Jun 2012 by FirstWord Pharma USD $695 More Info

This report is published by Current Partnering

Download Free Report Summary PDF

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2017 [Report Updated: 01-09-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data